Vascepa (icosapent ethyl) costs around $354 for a 30-day supply of 120 capsules without insurance, roughly $2.95 per capsule. That price reflects a combination of factors: a pharmaceutical-grade manufacturing process far more complex than ordinary fish oil, a massive clinical trial program, and a complicated patent landscape that has only partially opened the door to generic competition.
It’s Not Fish Oil
The single biggest factor behind Vascepa’s price is what it takes to make it. The active ingredient is a highly purified form of EPA, one of the omega-3 fatty acids found in fish oil. But while a typical prescription omega-3 product contains about 43% EPA, Vascepa must contain at least 96%. Reaching that level of purity requires multiple rounds of distillation and chromatography, essentially filtering and separating the compound again and again until nearly everything except EPA has been removed. There are no synthetic chemical steps involved, just an extremely refined purification process applied to fish oil that has been converted into an ethyl ester form.
This matters because the FDA regulates Vascepa as a drug, not a supplement. Every batch must meet strict pharmaceutical purity standards, and the manufacturing facilities undergo regular FDA inspection. Over-the-counter fish oil capsules face none of these requirements, which is one reason a bottle of fish oil costs $15 while a month of Vascepa costs over $350.
A Seven-Year, 8,000-Patient Clinical Trial
Vascepa’s price also reflects the cost of proving it works. The landmark REDUCE-IT trial enrolled 8,179 patients and ran from November 2011 to May 2018. That’s nearly seven years of tracking cardiovascular outcomes across a large patient population, a type of trial that typically costs hundreds of millions of dollars. The trial demonstrated that Vascepa reduced the risk of heart attacks, strokes, and other major cardiovascular events in patients already taking statins, a finding significant enough to earn the drug a second FDA indication.
Amarin, the company behind Vascepa, is relatively small compared to major pharmaceutical players. It doesn’t have a broad portfolio of drugs generating revenue to subsidize development costs. Vascepa is essentially the company’s only product, meaning the entire cost of that trial and the years of regulatory work surrounding it must be recovered from a single drug’s sales.
What Vascepa Is Actually Approved For
The FDA has approved Vascepa for two specific uses. The first is reducing triglyceride levels in adults with severe hypertriglyceridemia (levels at or above 500 mg/dL). The second, broader indication is reducing the risk of heart attack, stroke, coronary revascularization, and unstable angina in adults with elevated triglycerides (150 mg/dL or higher) who already have cardiovascular disease, or who have diabetes plus two or more additional heart risk factors. In both cases, it’s used alongside diet changes and statin therapy.
These FDA-approved indications are important because they’re what separates Vascepa from supplements in the eyes of insurers. A drug with proven cardiovascular outcomes data can be covered by insurance plans, while a fish oil supplement cannot. That regulatory distinction is part of the business model that supports the higher price point.
Generic Competition Exists, but It’s Limited
You might expect generics to have driven the price down significantly by now, and some generic versions do exist. Hikma launched a generic in late 2020, Dr. Reddy’s followed in mid-2021, and Apotex entered the market in January 2022. However, there’s an important catch: these generics are only approved for the original, narrower indication of reducing severely high triglycerides. They do not carry labeling for the cardiovascular risk reduction indication that came out of the REDUCE-IT trial.
This happened because a U.S. District Court in Nevada invalidated several of Amarin’s patents covering the original triglyceride-lowering use in March 2020. But the patents protecting the cardiovascular risk reduction use remain intact, with expiration dates stretching from 2030 to 2033. So if your doctor prescribes Vascepa specifically to lower your cardiovascular risk (which is the more common reason it’s prescribed today), a pharmacist may not be able to substitute a generic depending on your state’s substitution laws and your insurer’s formulary rules. This partial generic competition has put some downward pressure on pricing but hasn’t collapsed it the way full generic entry typically does.
Does the Cost Match the Benefit?
A Canadian cost-effectiveness analysis published in 2023 calculated that over a patient’s lifetime, Vascepa adds about $16,764 in drug costs compared to not taking it. But that increase is partially offset by savings from fewer cardiovascular events: roughly $4,075 saved from preventing first events and another $622 from preventing subsequent ones. The net additional cost works out to about $12,523 per patient, which buys an estimated 0.29 additional quality-adjusted life years.
In health economics terms, that translates to about $42,797 per quality-adjusted life year gained. Most health systems consider anything under $50,000 per quality-adjusted life year to be good value, and the analysis found a 70% probability that Vascepa meets that threshold. At a $100,000 threshold, which is commonly used in the United States, the probability jumped to nearly 99%. In other words, the drug is expensive in absolute terms, but preventing even one heart attack or stroke offsets a meaningful chunk of the cost, and the overall value proposition holds up under economic modeling.
Ways to Lower Your Out-of-Pocket Cost
If you have commercial insurance, your actual co-pay for Vascepa may be significantly lower than the $354 cash price, depending on your plan’s formulary tier. Amarin offers a Vascepa Savings Card that can reduce co-pays for eligible patients with commercial insurance. You can check eligibility by calling 855-497-8462 or visiting the program’s website. If your plan covers the generic version of icosapent ethyl, that will typically cost less, though availability varies by pharmacy and region.
For patients without insurance or with high-deductible plans, asking your pharmacist to compare the cash price of generic icosapent ethyl against the brand name is worth doing. The generic is only labeled for the severe triglyceride indication, but it contains the same active ingredient at the same purity, and your doctor can prescribe it off-label for cardiovascular risk reduction if appropriate.